The global women’s healthcare market is expected to grow at a CAGR of 9.78% from 2021 to reach USD 19.8 billion by 2027. The growth is mainly ascribed by the prevalence of chronic health disorders among women, government initiatives aimed to control population and prevention of unwanted pregnancies and R&D in women’s health products.
The global women’s healthcare market study provides market data for-by drug (EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL and ORTHO TRI-CY LO (28), by application (hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, polycystic ovary syndrome, and other applications). The study also evaluates industry competitors and analyses the market at a regional and country level.
Women’s Healthcare Market Overview (2021-2027)
- Forecast CAGR (2021-2027): 9.78%
- Forecast Market Size (2027): 19.8 billion
The global women’s healthcare market study provides market data for-by drug (EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL and ORTHO TRI-CY LO (28), by application (hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, polycystic ovary syndrome, and other applications). The study also evaluates industry competitors and analyses the market at a regional and country level.
Women’s healthcare market showed highest growth for Proila segment during the forecast period. The increased growth is accounted for the use in postmenopausal osteoporosis, prevalence of obesity in women and increasing population of older women.
Postmenopausal osteoporosis segment accounted for largest share of women’s healthcare market in 2020. The large market share of this segment can be attributed to increasing population of older women and introduction of various related drugs to cure menopausal osteoporosis.
Request For Free Sample Report @ https://www.sperresearch.com/report-store/Women-Health-Care.aspx?sample=1
Women’s Healthcare Market Key Segments Covered
The SPER Market Research report seeks to give market dynamics, demand, and supply forecasts for the years up to 2027. This report contains statistics on product type segment growth estimates and forecasts.
By Drug:
- EVISTA
- XGEVA
- Prolia
- Mirena
- Zometa
- Reclast/Aclasta
- Minastrin 24 Fe
- NuvaRing
- FORTEO
- Premarin
- ACTONEL
- ORTHO TRI-CY LO
By Application:
- Hormonal Infertility
- Postmenopausal Osteoporosis
- Endometriosis
- Contraceptives
- Menopause
- Polycystic Ovary Syndrome
- Other
By Region:
- North America
- Europe
- Asia-Pacific
Women’s Healthcare Market Key Players:
This study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as: Bayer AG (Germany), Allergan (Dublin), Merck & Co. (US), Pfizer Inc. (US), Amgen (US), Agile Therapeutics Inc. (US), Ferring Pharmaceuticals (US), Mylan N.V. (US), Lupin (India), Blairex Laboratories (US), Apothecus Pharmaceutical (US), Eli Lilly And Company (US), Novartis AG (Switzerland), Johnson & Johnson (US).
Contact Us:
Sara Lopes, Business Consultant – U.S.A.
SPER Market Research
+1-347-460-2899
About Author
